Actualities in Ovarian Cancer in the Perspective of 2015 (ASCO and ECCO)

Chirurgia (Bucur). 2016 Jan-Feb;111(1):9-11.

Abstract

Ovarian cancer represents the 4-th reason of cancer related death in women, the majority of patients being diagnosed in advanced stages of the disease, (III-IV). The loco-regional advanced ovarian cancer should be considered a chronic disease, with multiple evolutionary relapses and where the adjuvant treatment is mandatory.The treatment of the disease is multidisciplinary and the oncologist is the centerpiece.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / administration & dosage
  • Biomarkers, Tumor / blood*
  • Chemotherapy, Adjuvant / methods
  • Early Detection of Cancer
  • Evidence-Based Medicine
  • Female
  • Genes, BRCA1*
  • Genes, BRCA2*
  • Humans
  • Mutation*
  • Ovarian Neoplasms* / blood
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / mortality
  • Phthalazines / administration & dosage
  • Piperazines / administration & dosage
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Phthalazines
  • Piperazines
  • Bevacizumab
  • olaparib